{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T19:35:19Z","timestamp":1758396919104,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T00:00:00Z","timestamp":1581292800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T00:00:00Z","timestamp":1581292800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001922","name":"Efficacy and Mechanism Evaluation Programme","doi-asserted-by":"publisher","award":["13\/50\/17 APRICOT"],"award-info":[{"award-number":["13\/50\/17 APRICOT"]}],"id":[{"id":"10.13039\/501100001922","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012112","name":"Swedish Orphan Biovitrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Current treatment options for Palmoplantar Pustulosis (PPP), a debilitating chronic skin disease which affects the hands and feet, are limited. The Anakinra for Pustular psoriasis: Response in a Controlled Trial (APRICOT) aims to determine the efficacy of anakinra in the treatment of PPP. This article describes the statistical analysis plan for the final analysis of this two-staged trial, which was determined prior to unblinding and database lock. This is an update to the published protocol and stage one analysis plan.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>APRICOT is a randomised, double-blind, placebo-controlled trial of anakinra versus placebo, with two stages and an adaptive element. Stage one compared treatment arms to ensure proof-of-concept and determined the primary outcome for stage two of the trial. The primary outcome was selected to be the change in Palmoplantar Pustulosis Psoriasis Area and Severity Index (PPPASI) at 8 weeks. Secondary outcomes include other investigator-assessed efficacy measures of disease severity, participant-reported measures of efficacy and safety measures. This manuscript describes in detail the outcomes, sample size, general analysis principles, the pre-specified statistical analysis plan for each of the outcomes, the handling of missing outcome data and the planned sensitivity and supplementary analyses for the second stage of the APRICOT trial.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Discussion<\/jats:title>\n<jats:p>This statistical analysis plan was developed in compliance with international trial guidelines and is published to increase transparency of the trial analysis. The results of the trial analysis will indicate whether anakinra has a role in the treatment of PPP.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Trial registration<\/jats:title>\n<jats:p>ISCRTN, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.isrctn.com\/ISRCTN13127147\">ISCRTN13127147<\/jats:ext-link>. Registered on 1 August 2016. EudraCT Number <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2015-003600-23\">2015-003600-23<\/jats:ext-link>. Registered on 1 April 2016.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13063-020-4103-z","type":"journal-article","created":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T17:02:50Z","timestamp":1581354170000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A randomised placebo controlled trial of anakinra for treating pustular psoriasis: statistical analysis plan for stage two of the APRICOT trial"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6113-1173","authenticated-orcid":false,"given":"Suzie","family":"Cro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prakash","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Barker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Burden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher E. M.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen J.","family":"Lachmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick J.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard B.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Capon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Cornelius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,10]]},"reference":[{"key":"4103_CR1","doi-asserted-by":"crossref","unstructured":"Marsland AM, Chalmers RJ, Hollis S, Leonardi-Bee J, Griffiths CE. Interventions for chronic palmoplantar pustulosis. Cochrane Database Syst Rev. 2006;25(1):Cd001433.","DOI":"10.1002\/14651858.CD001433.pub2"},{"issue":"11","key":"4103_CR2","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1038\/jid.2013.267","volume":"133","author":"M Li","year":"2013","unstructured":"Li M, Han J, Lu Z, Li H, Zhu K, Cheng R, et al. Prevalent and rare mutations in IL-36RN gene in Chinese patients with generalized pustular psoriasis and psoriasis vulgaris. J Invest Dermatol. 2013;133(11):2637\u20139.","journal-title":"J Invest Dermatol."},{"issue":"3","key":"4103_CR3","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.ajhg.2011.07.022","volume":"89","author":"A Onoufriadis","year":"2011","unstructured":"Onoufriadis A, Simpson MA, Pink AE, Di Meglio P, Smith CH, Pullabhatla V, et al. Mutations in IL36RN\/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet. 2011;89(3):432\u20137.","journal-title":"Am J Hum Genet."},{"issue":"7","key":"4103_CR4","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1056\/NEJMoa1013068","volume":"365","author":"S Marrakchi","year":"2011","unstructured":"Marrakchi S, Guigue P, Renshaw BR, Puel A, Pei XY, Fraitag S, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365(7):620\u20138.","journal-title":"N Engl J Med."},{"issue":"1","key":"4103_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1186\/s13063-018-2841-y","volume":"19","author":"V Cornelius","year":"2018","unstructured":"Cornelius V, Wilson R, Cro S, Barker J, Burden D, Griffiths CEM, et al. A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trial. Trials. 2018;19(1):465.","journal-title":"Trials."},{"issue":"1","key":"4103_CR6","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1186\/s13063-018-2914-y","volume":"19","author":"S Cro","year":"2018","unstructured":"Cro S, Smith C, Wilson R, Cornelius V. Treatment of pustular psoriasis with anakinra: a statistical analysis plan for stage 1 of an adaptive two-staged randomised placebo-controlled trial. Trials. 2018;19(1):534.","journal-title":"Trials."},{"issue":"6","key":"4103_CR7","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/j.1365-2133.1988.tb03499.x","volume":"119","author":"A Lassus","year":"1988","unstructured":"Lassus A, Geiger JM. Acitretin and etretinate in the treatment of palmoplantar pustulosis: a double-blind comparative trial. Br J Dermatol. 1988;119(6):755\u20139.","journal-title":"Br J Dermatol."},{"issue":"sep14 1","key":"4103_CR8","doi-asserted-by":"publisher","first-page":"e5840","DOI":"10.1136\/bmj.e5840","volume":"345","author":"B. C. Kahan","year":"2012","unstructured":"Kahan BC, Morris TP. Reporting and analysis of trials using stratified randomisation in leading medical journals: review and reanalysis. BMJ. 2012;345:e5840.","journal-title":"BMJ"},{"issue":"7","key":"4103_CR9","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1002\/sim.5667","volume":"32","author":"BC Kahan","year":"2013","unstructured":"Kahan BC, Morris TP. Analysis of multicentre trials with continuous outcomes: When and how should we account for centre effects? Stat Med. 2013;32(7):1136\u201349.","journal-title":"Stat Med."},{"issue":"4","key":"4103_CR10","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/sim.4780080410","volume":"8","author":"SJ Senn","year":"1989","unstructured":"Senn SJ. Covariate imbalance and random allocation in clinical trials. Stat Med. 1989;8(4):467\u201375.","journal-title":"Stat Med."},{"issue":"9263","key":"4103_CR11","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/S0140-6736(00)04337-3","volume":"357","author":"D Moher","year":"2001","unstructured":"Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001;357(9263):1191\u20134.","journal-title":"Lancet."},{"key":"4103_CR12","unstructured":"European Medicines Agency. Guideline on adjustment for baseline covariates in clinical trials. London: 2015. EMA\/CHMP\/295050\/2013."},{"issue":"30","key":"4103_CR13","doi-asserted-by":"publisher","first-page":"5445","DOI":"10.1002\/sim.3068","volume":"26","author":"RM Pickering","year":"2007","unstructured":"Pickering RM, Weatherall M. The analysis of continuous outcomes in multi-centre trials with small centre sizes. Stat Med. 2007;26(30):5445\u201356.","journal-title":"Stat Med."},{"key":"4103_CR14","volume-title":"Missing data in randomised controlled trials - a practical guide","author":"J Carpenter","year":"2007","unstructured":"Carpenter J, Kenward MG. Missing data in randomised controlled trials - a practical guide. Birmingham: National Institute for Health Research; 2007."},{"issue":"4","key":"4103_CR15","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/sim.4067","volume":"30","author":"IR White","year":"2011","unstructured":"White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med. 2011;30(4):377\u201399.","journal-title":"Stat Med."},{"issue":"1","key":"4103_CR16","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/1471-2288-12-184","volume":"12","author":"J Hardt","year":"2012","unstructured":"Hardt J, Herke M, Leonhart R. Auxiliary variables in multiple imputation in regression with missing X: a warning against including too many in small sample research. BMC Med Res Methodol. 2012;12(1):184.","journal-title":"BMC Med Res Methodol."},{"key":"4103_CR17","volume-title":"Multilevel and longitudinal modeling using stata","author":"S Rabe-hesketh","year":"2012","unstructured":"Rabe-hesketh S, Skrondal A. Multilevel and longitudinal modeling using stata. Third ed. College Station: Stata Press; 2012.","edition":"Third ed."},{"issue":"3","key":"4103_CR18","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1177\/1740774513485311","volume":"10","author":"RC Zink","year":"2013","unstructured":"Zink RC, Wolfinger RD, Mann G. Summarizing the incidence of adverse events using volcano plots and time intervals. Clin Trials. 2013;10(3):398\u2013406.","journal-title":"Clin Trials."},{"issue":"7","key":"4103_CR19","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1002\/sim.1981","volume":"24","author":"IR White","year":"2005","unstructured":"White IR, Thompson SG. Adjusting for partially missing baseline measurements in randomized trials. Stat Med. 2005;24(7):993\u20131007.","journal-title":"Stat Med."},{"issue":"9","key":"4103_CR20","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1177\/0962280216683570","volume":"27","author":"TR Sullivan","year":"2018","unstructured":"Sullivan TR, White IR, Salter AB, Ryan P, Lee KJ. Should multiple imputation be the method of choice for handling missing data in randomized trials? Stat Methods Med Res. 2018;27(9):2610\u201326.","journal-title":"Stat Methods Med Res."},{"issue":"23","key":"4103_CR21","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1001\/jama.2017.18556","volume":"318","author":"C Gamble","year":"2017","unstructured":"Gamble C, Krishan A, Stocken D, lewis s, Juszczak e, Dor\u00e9 c, et al. Guidelines for the content of statistical analysis plans in clinical trials. JAMA. 2017;318(23):2337\u201343.","journal-title":"JAMA."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-4103-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-020-4103-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-4103-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T01:53:31Z","timestamp":1612835611000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-020-4103-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,10]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4103"],"URL":"https:\/\/doi.org\/10.1186\/s13063-020-4103-z","relation":{},"ISSN":["1745-6215"],"issn-type":[{"type":"electronic","value":"1745-6215"}],"subject":[],"published":{"date-parts":[[2020,2,10]]},"assertion":[{"value":"13 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The APRICOT trial is being conducted in compliance with the principles of the Declaration of Helsinki (1996), the principles of GCP and in accordance with all applicable regulatory requirements. Ethical approval was granted from the London Dulwich Research Ethics Committee (REC), (16\/LO\/0436). The protocol and study has also been approved by the Health Research Authority (HRA) (Ref: 162093) and the Medicines and Healthcare products Regulatory Agency (MHRA) for Clinical Trial Authorisation (Ref: 11387\/0026\/001). Patients receive an information sheet and provide written informed consent prior to participating in study specific procedures.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CS declares departmental research funding from AbbVie, GSK, Pfizer, Novartis, Regeneron, and Roche. CS is a PI on consortia (BIOMAP  and PSORT ) which have a number of industry partners. HJL declares funding from SOBI to support a nurse post in systemic autoinflammatory diseases. FC declares having received funding from Boehringer-Ingelheim and AnaptysBio. DAB declares honoraria for lectures, research or advisory boards from Abbvie, Almirall, Boehringer Ingelheim, Celgene, Janssen, Lilly, Novartis and UCB pharma. CEWG declares AbbVie (AD Board), Almirall (Consultant), BMS (Speaker), Galderma (AD Board), Janssen (Consultant\/Speaker), LEO (Speaker), Lilly (AD Board\/speaker), Novartis (AD Board\/Speaker), Pfizer (AD Board), Samsung Bioepis (Consultant), Sandoz (AD Board), CG Skin (Stockholder), SynDermix (Consultant), UCB Pharma (AD Board), Walgreens Boots Alliance (AD Board\/Speaker) and Celgene (AD Board\/Speaker). No competing interests are known for the other authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"158"}}